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Summary
In this study, we explore and discuss nanoparticles and
nanoscale materials and their use in medicine (nanomedi-
cine) and pharmaceutics (nanopharmaceutics). The study
is aimed at shedding light on this highly multidisciplinary
research field and at examining the influence of research
funding, industrial applications, and legal and regulatory
frameworks on the research in this field, a clear under-
standing of which is essential to efficiently support the
translation of research findings into industrial and clinical
applications and to enable access to a larger society.
Key words: nanotechnology; nanomedicine; nanoparticle;
translational research
Introduction
For over thirty years, intensive research has been conduc-
ted in the field of nanotechnology worldwide, in particular,
in the area of nanomaterials. In the last decade, products
containing nanomaterials, such as textiles, cosmetics, and
recently developed products for biomedical applications,
have entered the market at an increased pace. However,
specific “nano-effects” are not always emphasised on for
such products. In the late 1970s, C.G. Granqvist and R.A.
Buhrman [1] discovered nanoparticles and identified their
specific properties, calling them “ultrafine particles”.
These particles were mainly discussed because of their oc-
currence as natural particles, or they were considered by-
products of industrialisation with regard to their contri-
bution to air pollution and their impact on health. The
first publications dealing with “engineered nanoparticles”
were produced by the Australian and Swiss pharmacists J.J.
Marty, R.C. Oppenheim, and P. Speiser in 1978 [2, 3] and
by U. Schroder from Lund University in 1986 [4], who sug-
gested the use of inorganic nanoparticles for drug deliv-
ery. Only inorganic or organic particles of nano-sizes, but
not molecules or biological entities (like viruses), are con-
sidered nanoparticles even though these constructs are also
in the size range of nanometers. This is due to the scientif-
ic interest in the size-related physical and chemical proper-
ties that differ significantly from those observed in particles
with larger sizes or in bulk materials.
Over time, research and development of nanoparticles has
gathered wide attention and interest, and various research
initiatives have been launched worldwide (e.g., the Nation-
al Nanotechnology Initiative in the USA in the 1990s, the
European COST Action 523, the European Frameworks,
and national activities at a global scale).
Because of the vast response that nanoparticle-related re-
search and products have received in society, the adjunctive
ethical, legal, and social aspects – especially the oppor-
tunities and risks of nanoparticles and nanotechnology –
are investigated and discussed in this paper. Diagnostic
and medical applications are particularly important areas to
consider as nanotechnology offers many promises of im-
proved treatment and enhancement of the quality of life of
patients with respect to several diseases.
However, there are several concerns worldwide about nan-
otechnology and its possible toxic side-effects, and the leg-
al framework applicable to the use of these technologies
needs to be continuously explored and re-evaluated. In-
consistencies in definitions and standards in such an emer-
ging and increasingly prominent field like nanotechnology
could lead to uncertainties in patenting and regulatory bod-
ies when applying research findings to produce tangible
products.
Starting with a discussion regarding the definition of nano-
technology, this paper is focused on the describing the use
of nanotechnology in medical applications, discussing the
relevance of the novel properties of nanoparticles for med-
ical uses, and, finally, we aim to highlight the important as-
pects that influence the current research and development
as well as to disseminate the findings of the research in this
interesting field.
What is nanotechnology?
In 2003, a group of eleven experts in the field of na-
notechnology, philosophy, and risk assessment under the
auspice of the Europäische Akademie Bad Neuenahr-Ahr-
weiler GmbH discussed six existing definitions of nano-
technology and stated that “the lessons learned from the
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six definitions of Nanotechnology […] are that the existing
definitions of Nanotechnology sketch a fuzzy picture of
what Nanotechnology is about. These definitions are hardly
usable in concrete decision situations, and […] the respect-
ive purposes of definitions are essential in debating about
their appropriateness and adequateness.” They provided
their own definition of nanotechnology, thereby particu-
larly emphasising the fact that properties of nano-sized
substances should not have any equivalents in the mac-
roscopic world. Having specific size-dependent physical
properties such as magnetic, chemical, electronic, optical,
or thermodynamic properties, and being defined by a finite
number of constituents make nanoparticles unique and res-
ult in their inability to be described by classic physical laws
but only by quantum mechanics. As Schmid et al. explain
[5]: “Nanotechnology is dealing with functional systems
based on the use of sub-units with specific size-depend-
ent properties of the individual sub-units or of a system of
those.”
An example of a functional system could be a titanium ox-
ide nanoparticle in the anatase form as, with the size of
the crystallite, the wavelengths of absorbed light change.
Smaller particles, less than 10 nm in size, show a larger
band gap and absorb light of higher energy, like UV light.
Such particles are used today in products like sun-creams
because of their strong UV light-absorbing capabilities.
On the other hand, the commercial use of titanium oxide
particles of sizes between 10 and 100 nm, such as white
pigments in paints, papers, or toothpastes, does not qualify
them as functional systems, and, therefore, they cannot be
considered nanoparticles according to the definition given
by Schmidt et al. [5]. Such a strict definition can create a
number of issues as it can segregate a major area of re-
search activities and related products from the field of nan-
oparticles, nanotechnology, and other research areas deal-
ing with nano-sized particles. This may also create prob-
lems for regulators as they have to distinguish between
nanoparticles that fit the definition provided by Schmid
et al. [5] and other particles that are only nano-sized, or
ultra-small (fine) particles. Interestingly, the EU commis-
sion does not define “nanotechnology” but the term “nano-
particle” in a very precise manner: it states that a material
is a nanomaterial if more than 50% of the particles in this
material have at least one dimension between 1 nm and
100 nm [6]. Alternatively, it is also a nanomaterial if it has
a specific surface per unit volume larger than 60 m2/cm3.
According to this definition, graphene, naturally occurring
and incidental nano-sized materials, as well as manufac-
tured particles, are also included in nanomaterials; aggreg-
ates and agglomerates of such particles are also included.
Another major area of nanotechnology is based on effects
arising from the high surface-to-volume ratios of nanoscale
materials, such as the catalytic effect. For example, re-
searchers at Mobil Oil Co. were able to synthesize nano-
structured crystalline zeolite that, with a pore size of
0.45–0.6 nm, enabled the control of selectivity in petro-
chemical processes at the molecular level. Today, zeolite
catalysts are used in the processing of petroleum and chem-
icals at an industrial level. Metal nanoparticles supported
on oxides have become fundamental components of several
devices. Their nanosized structures with new chemical and
physical properties often result in a higher reactivity of
these surfaces relative to their bulk counterparts [7]. The
high surface-to-volume-ratio in nanoparticles can lead to
changes in the crystal structure and thus reduce the melting
temperature. Subsequently, the chemical and optical prop-
erties of the material are influenced.
Nano-effects in medical and
pharmaceutical applications
Overview
Materials used in particulate form for medical applications
in diagnostics and in drug delivery can be divided into
the following sub-groups: (a) liposomes, (b) polymeric mi-
celles, (c) polymer–drug conjugates, (d) dendrimers, (e)
oil nanoemulsions, (f) mesoporous silica nanoparticles, and
(g) iron oxide nanoparticles [8]. Javed [9] defines such con-
structs as nanopharmaceutics, “because of their size effect,
are capable of altering the properties of a drug, including
their bioavailability, biodistribution and pharmacokinet-
ics.” Alternatively, Bawa et al. [10] describe nanopharma-
ceuticsas colloidal particles of 10 to 1000 nanometers with
properties fundamentally different from objects of macro-
scopic sizes. In their description, they distinguish between
“therapeutic molecules” which represent a nanoformula-
tion themselves, from those that are coupled to a nano-
particulate carrier. Their published work points specifically
at Doxil®, Abraxane®, Diprivan®, DaunoXome®, Estras-
orb™, Macugen®, and Amphotec® as nanopharmaceuticals,
which were approved by the FDA between 1989 and 2005.
These were approved “according to pre-existing laws and
without any special testing (e.g., with respect to pharma-
cokinetic profiles)”. In addition, approvals of new nanod-
rugs and “nanoreformulations” are often granted for com-
plex combination products (carrier plus therapeutic molec-
ule) but the safety of the carrier, the therapeutic molecule,
and the interaction between these has to be studied and ap-
proved carefully in view of potential health and environ-
mental risks.
Essentially all types of inorganic and organic nanoparticles,
including liposomes, can be used as carriers for therapeutic
molecules and can be described as “complex combination
products.” However, even without molecules attached or
included, they have an affinity towards various proteins
that are always present in biological systems. Such binding
of nanoparticles to proteins takes place when used for in
vitro investigations (e.g., immune assays) and especially
when applied in vivo via the lymphatic system, the blood
system, or any other system in the body. This property of
initial rapid adsorption of proteins on biomaterial surfaces
has been known since the early 1970s when the blood com-
patibility of biomaterials was first investigated. In the case
of nanoparticles, the surface is much larger than that of
macro-devices. In addition, the particles are free-floating
and, depending on their passage to the targeted cell, tissue,
or organ, they may change their adhesion behaviour. The
surface coating (composition, charge, confirmation), mor-
phology of the particles, and size are crucial to the adsorp-
tion of proteins or other molecules. Assuming that such
nanoparticles can bind to or enter cells, cell compartments,
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or even the nucleus, they could potentially be used as thera-
peutic agent without further therapeutic molecules needing
to be attached. Such a nanoparticle could then potentially
act as a kind of “molecular therapy.” (A frequent opinion
is that molecular therapeutics target diseases at a molecular
level and thus modulates the disease at its roots.) However,
the techniques for the manipulation of the surface proteins
are not yet sufficiently elucidated to allow the nanoparticles
to be used as such at this stage.
The most thoroughly investigated nanomaterials today are
gold or iron oxide nanoparticles. The latter are applied in
medical diagnostics as contrast agents for imaging of the
liver, liver metastases, lymph nodes, cardiovascular dis-
eases, and inflammatory diseases such as arthritis. They
may also be used in therapy as vectors for the transport
of drugs and in the use of hyperthermia in the treatment
of cancer. The latter makes use of the intrinsic heating ef-
fect of magnetic nanoparticles when exposed to an external
magnetic field [11]. Most of these functional systems are
currently still at the research stage or used in clinical trials.
Superparamagnetic iron oxide nanoparticles
Superparamagnetic iron oxide nanoparticles or SPION –
a term also used in the following sections and which de-
scribes only nanoparticles of less than 30 nm and are
present as γ-Fe2O3 (maghemite) and Fe3O4 (magnetite) –
are particularly important to the health sector. It is im-
portant to note that magnetite has improved biocompatib-
ility, since the iron is completely oxidised (Fe3+), thereby
strongly reducing the formation of reactive molecules that
could damage the cells (oxidative stress). Nevertheless,
SPION need an additional coating with polymers that al-
lows for a longer residence time in the blood circulation
and the attachment of biomolecules such as antibodies.
This additional coating is an important feature essential
for magnetic resonance imaging (MRI), as it prevents the
particles from forming agglomerates due to the magnetic
interactions, which in turn could lead to problems such as
thrombosis or artifacts in imaging. Two superparamagnet-
ic contrast agents are clinically approved, namely ferumox-
ides (Feridex® in the USA, Endorem™ in Europe) with an
overall particle size (including polymers) of 150 nm, and
ferucarbotran (Resovist®) with a size of about 60 nm. Both
types of particles are coated with dextran and are approved
specifically for MRI of the liver.
With regard to hyperthermia, heating of the particles is
achieved by an alternating magnetic field through the Néel
relaxation process. As the relaxation time of the nano-
particles has to be in the range of medically acceptable
frequencies (100–300 kHz), the size of the particle must
be adjusted as precisely as possible to values between 15
and 25 nm. Under such conditions, the applied magnetic
field strengths should be below 6000 A/m (corresponding
to about 10 x 10–3 Tesla) to prevent the formation of un-
controlled “hot-spots” of high temperature in the body.
Examples of the application of SPION nanoparticles and
nanoformulations in medical therapy are being tested in
clinical trials or are already on the market, including drugs
used in cancer therapy. The nanoparticles are embedded in
a rigid polymer shell, called beads, and injected directly in-
to the tumour. The temperature that is generated by apply-
ing an alternating magnetic field is high enough to cause
the death of the tumour. Again, the scientific research is
still largely in its infancy, even though some companies are
conducting tests in clinical phases I–III for such particles
and related equipment (http://www.magforce.de/).
In addition to hyperthermia and medical therapies, a third
essential application of SPION is the separation of proteins.
All these applications often have a functional and biocom-
patible coating of the particles in common. Researchers
have used different natural or synthetic polymers for the
coating, but also inorganic materials such as silica or gold.
The most prominent coatings of SPION are dextran, poly-
ethylene glycol, and polyvinyl alcohol (PVA). In the case
of PVA-coated particles, biocompatible PVA functional-
ized with amino or carboxyl groups are used, which not
only serve for charge regulation but also as anchor points
for further attachment of peptides and proteins, including
antibodies and fluorescent dyes.
Gold nanoparticles are being used primarily for medical
analysis, utilising the effect of the local plasmon resonance,
which is based on the interaction between light as an elec-
tromagnetic wave and the free electrons (electronic con-
duction) in the metal. When light hits the gold nano-
particles, the free electrons oscillate together in the fre-
quency of the light from one side of the nanoparticle to the
other. The size of the particle determines the time required
for the electrons to oscillate. This way a dipole is formed
and light of a corresponding wavelength is absorbed. If
these wavelengths are in the visible light range, the effect
can be observed with the naked eye. Suspensions of small
(10 nm) gold particles absorb blue light and the compound
turns red, as can be observed for red church glass in which
the same effect can be visible. This effect can now be used
for rapid analysis of DNA defects [12]. Gold particles are
coated with a single strand of DNA complementary to the
corresponding DNA encoded in amino acid sequences that
are typical of the investigated disease. If a patient has the
disease, there is a highly specific binding of the patient’s
protein/peptide sequence to the complementary portion of
DNA already bound to the particles. Thus, this property of
nanoparticles can be used for simple, safe, and cost-effect-
ive disease detection. Other applications incorporate gold
particles in spectroscopic analytical methods, as discussed
above. Locally strong electromagnetic fields can be gen-
erated to stimulate molecules for spectroscopic studies, so
that the detection limit can be improved significantly (ex-
ample: Surface Enhanced Raman Spectroscopy).
Quantum dots
A third effect of these particles that could be of importance
in medicine is the phenomenon of quantum dot semicon-
ductors, which have a band gap between the valence band
and the conduction band. In a crystal with a diameter of
less than 10 nm, this band gap increases, and therefore
the wavelengths of both the absorbed and the emitted light
(blue shift of fluorescence) increase as well. Such particles
may be used as contrasting agents for optical microscopy,
where for each variable colour another antibody is
anchored on the particles and thus various components of
the cell can be observed simultaneously. For photothera-
peutic applications where a very precise adjustment of the
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wavelength of light is necessary, such particles can also be
used. The advantage of inorganic semiconductor nanocrys-
tals in the form of quantum dots is their high chemical and
optical stability compared with organic fluorophores. Un-
fortunately, however, most quantum dots that emit light in
the visible range are toxic and require an additional dense
inorganic coating of the surface. In most cases, this is made
of silica and an additional organic coating to improve the
biocompatibility [13].
Nanomedicine and nanopharmaceutics
– new fields in research and industry
Many definitions, many interpretations
Today, the term nanomedicine is essentially derived from
the definition of nanotechnology. In 2005 the European
Science Foundation (ESF) in its report titled ESF Forward
Look on Nanomedicine 2005 [6] issued the following state-
ment: “The field of ‘Nanomedicine’ is the science and tech-
nology of diagnosing, treating and preventing disease and
traumatic injury, of relieving pain, and of preserving and
improving human health, using molecular tools and mo-
lecular knowledge of the human body.”Problems may arise
with regard to the materials, technologies, or products that
can be labelled as “nano” and in deciding as to which
of these materials (of sizes greater than 100 nm) have
been wrongly classified as “nanoparticles”. Etheridge et
al. [14] conducted an evaluation of clinical trials in which
44 different nanoscale or nanostructured materials were
defined in advance based on their relevance in nanomedi-
cine. A search of related citations of clinical studies was
performed. Around 800 clinical trials with potential
nanomedicinal applications or products were discussed
from the viewpoint of evaluating the types of products,
their application in development, or, if already on the mar-
ket, their current use. Trials were conducted for 141 unique
applications and products; 38 already approved products
were investigated for new applications and the remaining
ones for new innovative products. Most of the applications
were cancer-related, followed by infectious diseases. The
diagnostic area, i.e., in vitro testing and in vivo imaging,
comprises mostly nanoparticle application while the device
area covering implant coatings and bone substitution often
uses larger nanoparticles (>100 nm) and microparticles.
Both investigational and commercial applications show
clearly that in therapeutic applications the investigational
products predominate even in the most cited area of cancer,
while for diagnostics/devices a rather different picture can
be seen. Etheridge demonstrated that around 60% of the
reviewed investigational and commercial products have a
size greater than 100 nm and therefore they would not be
considered as nanomedicine products if the definitions of
the EU or the guidelines of the FDA [15] were to be used.
This also provides an indication of the challenges, which
are related to the legal barriers for nanoscaled products in
medicine – risk evaluation, toxicity evaluation, and formu-
lations. To incorporate nanomedicine-based investigational
products into marketable applications, it does not seem ne-
cessary to encourage scientists to recreate more nanophar-
maceutics and nanoscale or nanostructured materials; in-
stead, it is essential to evaluate the existing materials, to
increase the understanding of the underlying physicochem-
ical and biological mechanisms, and to discuss the vari-
ous options for translational research to be undertaken by
centres for clinical trials and companies interested in the
development of such materials. Such an approach is only
possible if scientists and engineers, clinicians and the man-
agement of companies develop common research stand-
ards and make commitments in first-class research to the
characterisation of materials, standards for toxicity tests de-
pending on the various materials, and standards for pub-
lications, i.e., for materials, processes, and methods used
for high-quality research and development. It is further re-
commended to stress the importance of discussing the out-
comes of tests showing no toxicity effect [16] and that
company-based research, which is partially funded by gov-
ernmental or societal monies, should be published (propri-
etary reasons come first but after a certain time the inform-
ation should be open to the public). Finally, as mentioned
by Bleeker et al. [17], it is essential to introduce definitions
that cover not only the requirements for industrial nano-
particles, but also for nanoproducts as defined by EU and
European Medicines Agency EMA.
Nanoformulations as “re-inventions”
The advantages of nanotechnology, nanoparticles, or
nanomedicine over conventional technologies emanate
mainly from new features related to their considerable
small sizes. However, such sizes may exceed 100 nm, es-
pecially in nanomedicine when dealing with larger molec-
ules, which also have interesting characteristics.
The main drivers to translate nanotechnology into medi-
cinal products such as nano-based drugs are the potential
solutions offered by miniaturisation to fundamental prob-
lems like poor water solubility of drugs. In conventional
processes drugs need toxic organic solvents [18] and show
a lack of target specificity [10]. Existing pharmaceuticals,
however, can be “re-invented” with new nanoformulations
(re-use of drugs in nanoformulations when patents expire)
and thus reduce the cost of drug discovery, design, and
development. An example is the recently FDA-approved
“solvent-free formulation of paclitaxel for the treatment
of metastatic breast cancer that utilises 130–nanometer
albumin-bound (nab™) technology (Abraxane®; nab-pacl-
itaxel) to circumvent the requirement for solvents” [19].
An interesting approach to underscore the various require-
ments for a nanoparticulated drug (or “nanodrug”) strategy
is presented by Y. Liu [20]. The author distinguishes
between active and passively targeted nanodrugs, whereby
the passive targeting to tissues or organs is due to the
enhanced permeability of barriers and thus offers nano-
particles and nanodrugs a more accessible route to reach
the targeted area. Most of these products are taken up
by the reticulo-endothelial system and the nanodrug is re-
leased at the targeted site due to changes in certain physical
conditions like temperature or pH (thermal-sensitive and
pH-sensitive polymers). Targeting ligands (antibodies, lect-
ins, sugars, hormones, among others.), which identify the
cell/tissue receptor, can enhance the active targeting and by
using external excitation conditions (such as IR light and
a magnetic field) can also release the drug, thus improving
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efficacy. Nevertheless, the basis for such considerations is
that the physical space of the drug is reduced, that its physi-
cochemical and biological properties are changed due to its
small sizes, and that it can enter cells or pass barriers more
easily (e.g., the blood-brain barrier) and thus enhance the
bio-availability of the drug.
Liu discusses three types of drug-loaded nanoparticles. The
first refers to the “common drug-loaded particles” in a
nanoformulation, which creates an unsteady physicochem-
ical state; these are readily degraded. The second type is
the “controlled-release drug-loaded particles,” having a re-
lease process that follows a specific law, and these particles
are designed to release a specific concentration of the drug
for a specific tissue. Type 3 covers the “targeting drug-
loaded particles,” which are the most specific type of nano-
particles that may have different affinities to different cells
and can be activated under the influence of external forces
(e.g., magnetic forces). The companies involved with nan-
odrugs chiefly follow the first approach of “common drug-
loaded particles” in a nanoformulation, as shown by R.
Gaspar in a report entitled Nanomedicines Challenges and
Opportunities in a Global Development Environment [21].
The author distinguishes between the different forms in
which nanodrugs can be delivered: (i) nanocrystals
(already marketed as Rapam®, Emend®, or Megace®, and
other products that are currently in clinical trials, such as
silver or paclitaxel); (ii) liposomal and lipid products, many
of which are currently in clinical development, while oth-
ers, such as doxorubicin for cancer or amphotericin B for
fungal infections, are already marketed; (iii) polyethylene-
glycol (PEG)-based polymer-protein conjugates (PEG-In-
terferon alpha 2b (marketed)) and polymer-drug conjugates
which are in clinical phases (paclitaxel). “Controlled-re-
lease drug-loaded particles” or “targeting drug-loaded
particles” like iron oxide nanoparticles for MR imaging
are still in development or in clinical trials. Their pro-
cessing is not comparable with the other nanodrugs and
mainly based on conventional processes described earlier.
The nanoparticles are partially biodegradable (for example,
SPION in the liver are biodegradable but not in the kid-
neys) and they require the drug to be loaded on the surface.
Therefore, their behavior in the human body (long-term
toxicity, biodistribution, and degradation) is more question-
able and still under investigation.
Nano in translation
What conclusions should be drawn by the research commu-
nity in the field of nanotechnology and nanomaterials? This
question is particularly essential for research funding in the
field of nanoparticles. First, it is important to recognise the
achievements of researchers and research funding organ-
isations in having been able to take the complex field of na-
notechnology from fundamental research toward develop-
ment and innovation in only two decades. It is not the nano-
particles or nanotechnology research per se, but their use in
marketable applications (innovations) which are now at the
forefront. The shift of nanotechnology and nanoparticle re-
search toward the development of applications means that
funding is connected increasingly tight to industrial sectors.
These include the energy sector (solar panels, batteries, car-
bon nanotubes, reinforced composites for wind turbines,
or lightweight constructions), the health sector for contrast
and therapeutic agents used for the great challenges such
as central nervous system disorders (Alzheimer’s, Parkin-
son’s, and multiple sclerosis), various cancers, inflammat-
ory and autoimmune diseases like rheumatoid arthritis, and
cardiovascular diseases. Information technology also de-
pends on micro- and nanotechnology like nanostructured
polymer films known as organic light-emitting diodes,
transistors based on nanoscale printing processes, and
nanometer-scale magnetic tunnel junctions enabling very
fast and effective magnetic random access memory
(MRAM). In other words, nanotechnology has become the
“enabling technology” for which it was developed in the
first place. Nanotechnology today is accepted by a large
sector of the industry and, when fully developed and ap-
plied, it has potential to provide products of greater value
if production processes can be accelerated or become less
expensive. Therefore, scientific innovation in this area is
turning into an industrial innovation and the label “nan-
otechnology,” which initially helped to increase research-
funding opportunities, now enables researchers to meet the
real needs of the industry and consumers. The large number
of patents that has been filed during the last years can best




Today, the awareness of society to the potential dangers
of the use of new technologies is higher than ever before,
and questions that revolve around health and environment-
al influences need to be answered convincingly. Nano-
particles play an essential role in a variety of products
across all industries, including the health sector through
applications such as biomaterials, drug delivery, and nan-
odevices. The proportion of publications in the field of
nanotechnology that deals with various aspects of nan-
oparticles, covering synthesis, modification, and applica-
tion of these nanoparticles has increased about three times
within a decade, whereas the number of scientific public-
ations dealing with the issues of the toxicity of nanoma-
terials, particularly nanoparticles, has increased 30 times.
In connection with possible health risks, nanoparticles and
nanotubes and their applications are about one and a half
times more often cited in PubMed than articles dealing with
nanotechnology-based sensors or electronics.
In the area of nanoparticle toxicity in medical applications,
the quality of the research naturally plays a crucial role in
producing results that are meaningful for product develop-
ment. It appears that nanoparticles are often treated like
molecules and therefore existing methods, which are ap-
plied with great success in assessing the toxicity of chem-
icals and drug development, are often accepted without any
further examination of their applicability in studies to the
toxic effects of nanoparticles. Consequently, about 70–80%
of the literature covering the toxicity of nanoparticles may
be deemed unavailing, as explained by Harald Krug of the
Swiss Federal Laboratories for Materials Testing and Re-
search (EMPA), St. Gallen, Switzerland. He discussed this
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at the Spring Conference of the European Academy in Ber-
lin on 19, 20 April 2012, a fact which was recently con-
firmed by Patrick Boisseau, President of the European Plat-
form Nanotechnology at the annual meeting 2013 in Gren-
oble, France. To obtain results that are not influenced by
issues like the interactions between various nanoparticles
and contaminants or solvents that may be toxic due to the
system used or in themselves – for example, when using
MTT assays3, or the extremely high doses of nanoparticles
used in animal experiments – it is necessary to carefully
characterise the nanoparticles and to select test methods
which are suitable and validated for such investigations.
(An MTT assay is a colorimetric assay for measuring the
activity of cellular enzymes. It was found that the colourof
the observed particles interfere with the MTT test.)
Considering that nanomedicine deals with nanodrugs,
which are small-sized versions of already approved drugs,
and nanoparticle-based delivery systems based on inorgan-
ic nanoparticles that are still under investigation, it be-
comes clear that the quality of the disseminated results of
research in this field can only be improved by high-qual-
ity studies and by reliable and reproducible research. An
important and pioneering step towards increasing the qual-
ity of the research methods, tools, and the characterisation
of nanomaterials has been undertaken in the EU infrastruc-
ture project “QualityNano.” Its core aim is the creation of
a ‘neutral’ scientific and technical space in which all stake-
holder groups can engage, develop, and share best scientif-
ic practice in the field.
Journals and Editorial Boards should place more extensive
emphasis on the importance of details in describing mater-
ials and methods and allow reporting – especially in tox-
icity investigations – of important outcomes, for instance,
when stating that a nanomaterial is safe. Krug and Wick
[16] presented an action plan encompassing guidelines for
future publications that allow for the comparison of results
between studies, and for discussions and arguments to be
written in a style comprehensible by both experts and
laypersons. If these recommendations were to be followed,
it would also imply that part of the global financial funding
for nanoparticle and nanomedicinal research is currently
not efficiently used, as the outcome of some of the research
is questionable and not always reproducible.
Conclusions
Research in nanotechnology and nanoparticles is globally
funded and remains an influential “trendsetter” in research
and development because of its multidisciplinary nature
and because it interconnects multiple technologies.
Nanomedicine is an innovative sector in which nanotech-
nology and nanoparticles are used to improve the quality
of life of patients by providing earlier and more specific
diagnostic methods and better-targeted, less invasive meth-
ods of treatment. The definitions of nanotechnology and
nanoparticles, which imply specific size-related properties,
have focused mainly on size (<100 nm), while nanophar-
maceuticals use even larger sizes when dealing with so-
called nanoformulations of already approved drugs (up to
micron size). In this case, the definition of nanomedicine,
which is based on the definition of nanotechnology and
nanoparticles being less than 100 nm in size, cannot be ap-
plied.
After more than 20 years of intense nanotechnology re-
search, there is a clear trend towards application-oriented
research, especially in the biomedical field where versatile
tools for each application are no longer available. It be-
comes necessary to define the targeted field very early
in the research process and to find a marketable solution
very rapidly. It is more useful and less time-consuming to
find new nanoformulations for approved drugs than to start
afresh with inorganic nanocarriers for targeted drug deliv-
ery. This is particularly the case for large pharmaceutic-
al companies, which need a continuous revenue growth to
create shareholder value in a sustainable way. For diagnost-
ic devices and their nanoparticulate enhancers, the market
is even more challenging as the yearly increase in the num-
ber of device manufacturers is exceedingly low.
Aside from these market-based views, there are still safety
issues to be taken into account. Research has focused
chiefly on the risks and the ethical aspects of using nan-
oparticles in medicine and other application sectors. The
outcome of toxicity studies can be crucial and determine
the direction of further research and development towards
a possible product. If toxicity studies become an important
source of concern, it is recommended to reassess some of
the applied methods, to pay more attention to the materi-
al descriptions and characterisations and to their impact on
the results. The various action plans in place and further
discussed on national, European, and international levels
seek to standardise the research methodology and by this
to help improve the exchange of results. At national and
European levels, academic and industrial development in
the implementation of research findings from the laborat-
ory to the clinic (“bench to bedside”) is still hampered. This
is because the development of methods, the translation of
laboratory results to those of up-scaled materials and long-
term toxicology studies, and the standardisation of regulat-
ory testing require more infrastructure and guidelines that
are globally available and harmonised.
The initiative of the European Technology Platform (ETP)
Nanomedicine to establish a new “Nano-characterisation”
infrastructure [22] is a first important step in this direction.
The proposed centres or companies that could help scaling
up nanomaterials under good manufacturing practice
(GMP) control and regulatory standards, which otherwise
can only be produced in very small quantities under labor-
atory conditions, would help to accelerate the technology
transfer.
In conclusion, research with nanoparticles and nanopartic-
ulate systems used in diagnostics and therapy is well fun-
ded worldwide and results are widely disseminated through
a broad range of publications and patents. On the other
hand, large pharmaceutical companies have had to deal
with the issue of the so-called “patent cliff” for the past few
years: patents are bound to expire shortly and there is a risk
for sales to decrease dramatically. Nanoparticulate pharma-
ceutical systems based on well-known formulations may
help, especially if not hindered by legal issues. However,
in the case of combinatorial products like inorganic
nanoparticle-based drugs or nanoparticle-based biomarker
combinations, this proves to be especially difficult as re-
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search and development will require substantially more
time, and many challenges still need to be overcome in
view of enabling manufacturing processes, which are dif-
ficult to control and handling properties, which cannot be
fully characterised. Having to deal with various compon-
ents for one product (e.g., specific contrast agents for mo-
lecular imaging combining nanoparticles with biological
entities) will result in a dramatic increase in the expendit-
ures in relation to the research required by these products
and the legal work to support it. The large variety of some-
times overlapping definitions used in the nano-specific
field does not lead to greater levels of confidence. There-
fore, it is essential that the standards for toxicity tests are
improved and shared between the groups specialising in
the investigation of the toxicity of industrial nanoparticles
(high amounts and high environmental and health risks)
and pharmaceutical nanoproducts (low amounts, already
regulated under the EMA). Together with the leading
journals in the nanotechnology and nanomedicine fields,
high standards for publications focusing on materials, pro-
cesses, and methods should be put in place and the culture
of scientists and editors should slightly shift to accept the
“positive” outcomes of toxicity tests, which, in a sense,
show no effects as well. Such measures may result in a re-
duction of the number of published work in this field but
will, hopefully, lead to an improvement in the quality of the
research conducted in this area.
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